Clinical Trials on Oils, Essential

Total 945 results

Boehringer Ingelheim

Completed

Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension

Hypertension
Boehringer Ingelheim

Completed

Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

Hypertension
HK inno.N Corporation

Unknown

A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension

Essential Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension

Hypertension

China
Quantum Genomics SA

Completed

Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects

Essential Hypertension

France
Columbia University
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Motivational Interviewing

Essential Hypertension

United States
Boryung Pharmaceutical Co., Ltd
Pusan National University Hospital; Ulsan University Hospital; Daegu Catholic... and other collaborators

Completed

The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension

Hypertension

Korea, Republic of
University of Athens

Completed

Hybrid Blood Pressure Monitor Validation (NISSEI)

Essential Hypertension

Greece
Novartis

Completed

Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)

Hypertension
Novartis

Completed

Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension

Hypertension

Germany
Ahn-Gook Pharmaceuticals Co.,Ltd

Unknown

Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension

Essential Hypertension

Korea, Republic of
Novartis

Completed

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Hypertension

Slovakia, Italy, Netherlands, Argentina, Germany, Poland, Czech Republic, Iceland
Novartis

Completed

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

Essential Hypertension

Germany, Spain, United States
sigma-tau i.f.r. S.p.A.

Completed

Efficacy of Rostafuroxin in the Treatment of Essential Hypertension

Essential Hypertension

Belgium
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Hypertension

Sweden, United States, Peru, Russian Federation, Romania, Mexico, Panama, Spain, Denmark, Italy, Greece, South Africa, Canada, Argentina, Australia, Colombia, Finland, Taiwan
Yonsei University

Completed

Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension

Essential Hypertension

Korea, Republic of
Takeda

Completed

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

Essential Hypertension
Sankyo Pharma Gmbh

Completed

Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension (OLMETREAT)

Essential Hypertension

France, Austria, Switzerland, Belgium, Germany, Italy, Netherlands, United Kingdom, Portugal
Daiichi Sankyo, Inc.
Shanghai Sankyo Pharmaceuticals Co., Ltd.

Completed

Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension

Essential Hypertension

China
Daiichi Sankyo, Inc.
Shanghai Sankyo Pharmaceuticals Co., Ltd.

Completed

Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

Essential Hypertension

China
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers

Essential Hypertension
Boryung Pharmaceutical Co., Ltd
Seoul National University Hospital; Kyungpook National University Hospital

Completed

Study to Compare and Assess the Safety and Pharmacokinetic Characteristics After Oral Administration of Fimasartan (BR-A-657∙K) in Healthy Elderly and Young Male Volunteers (Fimasartan)

Essential Hypertension
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers

Essential Hypertension
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers

Essential Hypertension
Daiichi Sankyo, Inc.
Daiichi Sankyo Taiwan Ltd.

Completed

Olmesartan Medoxomil Versus Losartan in Patients With Hypertension

Essential Hypertension

Taiwan
Hanmi Pharmaceutical Company Limited

Completed

Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension

Hypertension

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K) (Fimasartan)

Essential Hypertension
Daiichi Sankyo, Inc.

Completed

Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension (Benibest)

Essential Hypertension
Addrenex Pharmaceuticals, Inc.

Completed

A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension

Hypertension

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Role of Endothelin in the Regulation of Vascular Tone in Patients With Essential Hypertension

Hypertension

United States
AstraZeneca

Completed

Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide (CoCa)

Essential Hypertension
Novartis

Completed

Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension

Hypertension

China
Pacific Pharmaceuticals

Unknown

Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension

Essential Hypertension

Korea, Republic of
Novartis

Completed

A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)

Hypertension

Switzerland
National Taiwan University Hospital

Unknown

A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension

Hypertension

Taiwan
Shire

Completed

A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients

Thrombocythemia, Hemorrhagic

Bulgaria, France, Hungary, Poland, Portugal, Serbia
Natural Wellness Egypt

Not yet recruiting

NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial

Essential Hypertension
Yuhan Corporation

Not yet recruiting

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
Hasten Biopharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study

Essential Hypertension

China
Chong Kun Dang Pharmaceutical

Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy

Essential Hypertension

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy

Essential Hypertension

Korea, Republic of
Chong Kun Dang Pharmaceutical

Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy

Essential Hypertension

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy

Essential Hypertension

Korea, Republic of
Shin Poong Pharmaceutical Co. Ltd.

Completed

Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension (SP-CAP-002)

Hypertension | Essential Hypertension

Korea, Republic of
Celltrion Pharm, Inc.

Completed

A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

Essential Hypertension

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension (HM_APOLLO)

Hypertension

Korea, Republic of
Handok Inc.

Completed

Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients

Essential Hypertension

Korea, Republic of
Shanghai Golden Leaf MedTec Co. Ltd

Completed

To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension

Hypertension

China
Servier

Completed

Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.

Essential Hypertension

Russian Federation
Hanmi Pharmaceutical Company Limited

Completed

A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension (HM_APOLLO)

Hypertension

Korea, Republic of

3

Subscribe